Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

Induction of potent CD8+ T cell responses through the delivery of subunit protein vaccines to skin antigen-presenting cells using densely packed microprojection arrays

“…[73][74][75]. Unlike Quil-A, CpG has been used in vaccine clinical trials, making our data on CpG adjuvant more relevant [70,76,77].…”

Prophylactic vaccinations in chronic kidney disease: Current status

“…50 In healthy adults 40 y of age, 3-dose regimen of HBsAg-1018 given at 0, 1, and 6 months demonstrated superior seroprotection with 2-3 doses when compared to the conventional hepatitis B vaccination. 51,52 In CKD subjects 18-75 y of age, 3 doses of HBsAg-1018 induced significantly higher, earlier, and more durable seroprotection than 4 double doses of the conventional hepatitis B vaccine. 53 However, HBsAg-1018 was associated with significantly more injection-site tenderness than the conventional vaccine (63.2% -81.8% vs. 15.4% -18.8%).…”

New developments in the era of viral hepatitis vaccines

“…One of the recently developed vaccine (HEPLISAV) which contains immune stimulant phosphorothioate oligodeoxyribonucleotide provides significantly higher response rates when compared with other third generation vaccines [15,16]. Also there are other studies by adding new adjuvants to HBV vaccine such as interferons, interleukins, etc.…”